BVS — Bioventus Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1665988 ·
Last close
$13.17
Market Cap
$892.24M
52W High
$13.55
52W Low
$7.81
ADV30
725,697
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 132,089,000 | 90,769,000 | 8,870,000 | 3,113,000 | 650,539,000 | 35,846,000 | 416,274,000 |
| Dec 2025 | 157,900,000 | 108,782,000 | 21,721,000 | 14,755,000 | 683,559,000 | 51,238,000 | 455,112,000 |
| Sep 2025 | 138,651,000 | 94,229,000 | 11,251,000 | 3,155,000 | 701,593,000 | 42,164,000 | 494,338,000 |
| Jun 2025 | 147,660,000 | 102,090,000 | 18,369,000 | 7,459,000 | 706,788,000 | 32,910,000 | 505,489,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$74,673,000
Investing CF
$-3,248,000
Financing CF
$-62,140,000
CapEx
$-2,562,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,929,000
Inventory
$82,236,000
Receivables
$128,303,000
ST Investments
—
EBIT TTM
$52,195,000
Pretax Income TTM
$25,709,000
Interest Exp TTM
$26,486,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$576,300,032
EBITDA
$80,897,000
Free Cash Flow
$63,310,876
Enterprise Value
$1,190,857,216
Total Cash
$35,846,000
Total Debt
$288,420,000
Shares Out
67,748,048
Trailing EPS
$0.41
Book Value
$2.79
ROE
16.5%
ROA
5.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 568,087,000 | 56,291,000 | 22,732,000 | 683,559,000 | 455,112,000 | — | 74,673,000 |
| Dec 2024 | 573,280,000 | 22,825,000 | -36,125,000 | 727,956,000 | 542,352,000 | — | 38,795,000 |
| Dec 2023 | 512,345,000 | 2,026,000 | -156,230,000 | 810,910,000 | 589,792,000 | — | 15,344,000 |
| Dec 2022 | 512,117,000 | -34,656,000 | -158,704,000 | 1,372,649,000 | 960,427,000 | — | -13,537,000 |
TTM Snapshot
Revenues TTM
$138,964,000
NetIncome TTM
$-5,165,000
OpCashFlow TTM
$0
Assets (Latest)
$727,956,000
Forward EPS
$0.91
Max Pain — expiry 2026-08-21
max pain strike: $10.00 · spot: $13.17 · call oi: 997 · put oi: 1,263
Expected Move to 2026-08-21:
±$2.58
(19.55%) —
implied range
$10.60 –
$15.75
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INMD | InMode Ltd. | $870.26M | $15.14 | — |
| STVN | Stevanato Group S.p.A. | $986.74M | $19.85 | — |
| SSII | SS Innovations International, Inc. | $796.52M | $3.98 | — |
| SIBN | SI-BONE, Inc. | $787.64M | $17.76 | — |
| AVR | Anteris Technologies Global Corp. | $763.16M | $7.84 | — |
News headlines (Yahoo Finance, 1h cache)
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-30 14:00 · Yahoo
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth
2026-07-29 14:00 · Yahoo
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
2026-07-29 12:30 · Yahoo
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
2026-07-27 13:40 · Yahoo
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
2026-07-24 13:55 · Yahoo
Bioventus (BVS) Upgraded to Buy: Here's Why
2026-07-22 16:00 · Yahoo
Should Value Investors Buy Bioventus (BVS) Stock?
2026-07-22 13:40 · Yahoo
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
2026-07-10 22:14 · Yahoo
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
2026-07-09 13:40 · Yahoo
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
2026-07-08 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.